|
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults Clinical research trials and Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults. Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults clinical trial. Subjects frequently obtain the most expert healthcare possible for their Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults  Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to test the safety of an HIV DNA vaccine (EP HIV-1090) and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people. This vaccine uses only parts of the virus's DNA and cannot cause HIV infection.
Details: Epidemiological and animal model data support the hypothesis that HIV specific cytotoxic T lymphocyte (CTL) responses contribute to control and clearance of the virus. Vaccines designed specifically to induce CTL responses are likely to be well suited for protection against HIV infection and disease progression. EP HIV-1090 is a DNA vaccine composed of 21 highly specific CTL epitopes. The vaccine is designed to optimize the immune response in people expressing one of three HLA Class I antigen subtypes: HLA-A2, -A3, and -B7. This design is predicted to induce an immune response in 85% of individuals in the general population. There is also a helper T lymphocyte (HTL) facilitating epitope (PADRE) in the vaccine. The vaccine is formulated with a water soluble polymer (polyvinylpyrrolidone) that protects the DNA and facilitates cellular uptake. This study will assess the safety of and immune response to different doses of EP HIV-1090 in healthy, HIV uninfected adults. Participants in this study will be randomized to receive either one of three different doses of vaccine or placebo. Participants will receive vaccinations or placebo at study entry and Months 1, 3, and 6. Both vaccinations and placebo are administered by intramuscular injection. Participants will be followed for 18 months and will have 12 study visits. Each study visit will include a physical exam, medical history, and blood and urine tests. Each participant will have four HIV tests during the study. Women will have at least five pregnancy tests during the study.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/40 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - HIV negative - Positive for one or more of the following HLA supertypes: -A2, -A3, or -B7 - Willing to receive HIV test results - Good general health - Acceptable methods of contraception for females of reproductive potential - Hepatitis B surface antigen negative - Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is positive Exclusion Criteria - HIV vaccines or placebos in prior HIV vaccine trial - Immunosuppressive medications within 168 days prior to first study vaccine administration - Blood products within 120 days prior to first study vaccine administration - Immunoglobulin within 60 days prior to first study vaccine administration - Live attenuated vaccines within 30 days prior to first study vaccine administration - Investigational research agents within 30 days prior to first study vaccine administration - Subunit or killed vaccines within 14 days prior to first study vaccine administration - Current tuberculosis prophylaxis or therapy - Active syphilis - Serious adverse reaction to vaccines. A person who had an adverse reaction to pertussis vaccine as a child is not excluded. - Autoimmune disease or immunodeficiency - Unstable asthma - Type 1 or Type 2 Diabetes Mellitus - Thyroid disease requiring treatment - Serious angioedema within the past 3 years - Uncontrolled hypertension - Bleeding disorder - Malignancy unless it has been surgically removed and, in the opinion of the investigator, is not likely to recur during the study period - Seizure disorder requiring medication within the past 3 years - Asplenia - Mental illness that would interfere with compliance with the protocol - Other conditions that, in the judgment of the investigator, would interfere with the study - Pregnant or breast-feeding
Total Enrollment: 42
Location and Contact Information:
Overall Study Official:
GeoffreyGorse, Study Chair, St. Louis University
Miriam Hosp
Providence, Rhode Island, 02906
United States
Harvard Med School/Brigham & Womens Hosp
Boston, Massachusetts, 02115
United States
Botswana HIV Vaccine Clinical Eval. Ctr
Gaborone, ,
Botswana
Fenway Community Health
Boston, Massachusetts, 02115
United States
St. Louis Univ - New Hope Bldg.
St. Louis, Missouri, 63110-2500
United States
Additional Information:
Study ID Numbers: HVTN 048;
Study Start Date:
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00054860
Other Hiv Infections Studies:
1. A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients with Dementia
2. Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma
3. Treatment of Advanced AIDS Patients with Dextrin Sulfate
4. A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
5. A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
Related Studies:
Other HIV Infections Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
|
|
|
|
|
|
|
|
